<p>Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 获取免费报告）在周一的交易中上涨了 0.3%。该股票最高交易价为 15.28 美元，最后交易价为 15.04 美元。交易期间大约有 12,602 股成交，较平均每日成交量 45,161 股下降了 72%。该股票此前收盘价为 15.00 美元。</p>
<p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析师评级上调与下调</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”。</p>
<p><strong>阅读我们对 COEP 的最新分析</strong></p>
<h2>Coeptis Therapeutics 股票表现</h2>
<p>该公司的债务与股本比率为 0.02，速动比率为 0.83，流动比率为 0.83。该公司的 50 日移动平均价格为 14.60 美元，200 日移动平均价格为 11.37 美元。该公司的市值为 7249 万美元，市盈率为-4.59，贝塔值为-0.49。</p>
<p>Coeptis Therapeutics（纳斯达克代码：COEP - 获取免费报告）最后一次公布季度财报是在 8 月 14 日星期四。该公司报告的每股收益（EPS）为-1.17 美元。该季度的营业收入为 20 万美元。</p>
<h2>Coeptis Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症（包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病）的细胞治疗；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同类型的肿瘤，包括血液恶性肿瘤和实体肿瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Coeptis Therapeutics</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>增长选择：3 只低成本股票可能会翻倍</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>这 3 只被打压的股票准备反弹吗？</li>
<li>如何投资小盘股</li>
<li>特朗普引发的量子股票反弹是否有持续性？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
<p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Coeptis Therapeutics 并不在名单上。</p>
<p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COEP

<p>Coeptis Therapeutics（纳斯达克代码：COEP）股价上涨 0.3%，交易价格为 15.04 美元，最高达到 15.28 美元。交易量较平均水平下降 72%，共交易了 12,602 股。分析师维持一致的 “卖出” 评级，Weiss Ratings 重申 “卖出（e+）” 评级。该公司报告的季度每股收益为（1.17 美元），收入为 20 万美元。Coeptis 专注于开发用于癌症治疗的细胞治疗平台，市值为 7249 万美元，债务与股本比率为 0.02</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) rose 0.3% during trading on Monday . The stock traded as high as $15.28 and last traded at $15.04. Approximately 12,602 shares changed hands during trading, a decline of 72% from the average daily volume of 45,161 shares. The stock had previously closed at $15.00.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP - 获取免费报告）在周一的交易中上涨了 0.3%。该股票最高交易价为 15.28 美元，最后交易价为 15.04 美元。交易期间大约有 12,602 股成交，较平均每日成交量 45,161 股下降了 72%。该股票此前收盘价为 15.00 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票目前的共识评级为 “卖出”。</p>
</div><p><strong>Read Our Latest Analysis on COEP</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 COEP 的最新分析</strong></p>
</div><h2>Coeptis Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.83 and a current ratio of 0.83. The company has a 50 day moving average price of $14.60 and a 200 day moving average price of $11.37. The company has a market capitalization of $72.49 million, a price-to-earnings ratio of -4.59 and a beta of -0.49.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.02，速动比率为 0.83，流动比率为 0.83。该公司的 50 日移动平均价格为 14.60 美元，200 日移动平均价格为 11.37 美元。该公司的市值为 7249 万美元，市盈率为-4.59，贝塔值为-0.49。</p>
</div><p>Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The business had revenue of $0.20 million during the quarter.</p>
<div class="lb-trans"><p>Coeptis Therapeutics（纳斯达克代码：COEP - 获取免费报告）最后一次公布季度财报是在 8 月 14 日星期四。该公司报告的每股收益（EPS）为-1.17 美元。该季度的营业收入为 20 万美元。</p>
</div><h2>Coeptis Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症（包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病）的细胞治疗；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同类型的肿瘤，包括血液恶性肿瘤和实体肿瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Are These 3 Beaten-Down Stocks Ready to Rebound?</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Does the Trump-Induced Quantum Stock Rally Have Legs?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Coeptis Therapeutics</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>增长选择：3 只低成本股票可能会翻倍</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>这 3 只被打压的股票准备反弹吗？</li>
<li>如何投资小盘股</li>
<li>特朗普引发的量子股票反弹是否有持续性？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Coeptis Therapeutics 并不在名单上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coeptis Therapeutics (NASDAQ:COEP) 的股价上涨了 0.3% - 以下是原因